Evidence map›Paper›PMID 41356265›Full record

ArticleOpen forum infectious diseases2025

T-cell Response Induced by the BNT162b2 COVID-19 Vaccine in Children.

Isabel Vogler, Stephanie Renken, Rolf Hilker, Bonny Gaby Lui, Andrew Finlayson, Alejandra Gurtman, Charulata Sabharwal, Nicholas Kitchin, Stephen Lockhart, William C Gruber and 4 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04816643 (A PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY CHILDREN), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04816643 phase3completednot on this map

A phase 1, open-label dose-finding study to evaluate safety, tolerability, and immunogenicity and phase 2/3 placebo-controlled, observer-blinded safety, tolerability, and immunogenicity study of a sars-cov-2 rna vaccine candidate against covid-19 in healthy children

TypeinterventionalSponsorBioNTech SERan2021 to 2023Enrolled11,837ConditionsSARS-CoV-2 Infection, COVID-19ArmsBiological/Vaccine: BNT162b2 10mcg, BNT162b2 20mcg, BNT162b2 30mcg, Placebo, Biological/Vaccine: BNT162b2 3mcg
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Isabel VoglerBioNTech SE, Mainz, Germany.
Stephanie RenkenBioNTech SE, Mainz, Germany.
Rolf HilkerBioNTech SE, Mainz, Germany.
Bonny Gaby LuiBioNTech SE, Mainz, Germany.
Andrew FinlaysonBioNTech SE, Mainz, Germany.ORCID https://orcid.org/0000-0003-0793-7878
Alejandra GurtmanVaccine Research and Development, Pfizer Inc., Pearl River, New York, USA.
Charulata SabharwalVaccine Research and Development, Pfizer Inc., Pearl River, New York, USA.
Nicholas KitchinVaccine Research and Development, Pfizer Ltd., Marlow, UK.ORCID https://orcid.org/0000-0002-1808-3380
Stephen LockhartVaccine Research and Development, Pfizer Ltd., Marlow, UK.ORCID https://orcid.org/0000-0002-0805-2193
William C GruberVaccine Research and Development, Pfizer Inc., Pearl River, New York, USA.ORCID https://orcid.org/0000-0002-6518-4547
Kathrin U JansenVaccine Research and Development, Pfizer Inc., Pearl River, New York, USA.
Kena A SwansonVaccine Research and Development, Pfizer Inc., Pearl River, New York, USA.ORCID https://orcid.org/0000-0002-3389-8414
Özlem TüreciBioNTech SE, Mainz, Germany.
Uğur ŞahinBioNTech SE, Mainz, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phase 1 and Phase 2/3 trials (NCT04816643) demonstrated that the mRNA-based coronavirus disease 2019 (COVID-19) vaccine BNT162b2 is tolerable and efficacious in (5-11-year-olds) following two 10 µg doses 21 days apart, and a third 10 µg dose after 6 months. Here, we show that vaccination induces neutralizing antibodies and T-cell immunogenicity in 10-11-year-old participants.

Indexed as

childrenCOVID-19SARS-CoV-2T-cell responsesvaccine

Identifiers

PMID41356265
PMCPMC12680099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.